Literature DB >> 33763078

The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients.

Huanle Luo1,2, Tingting Jia1, Jiamin Chen1, Shike Zeng1, Zengzhao Qiu1, Shu Wu1, Xu Li1, Yuxuan Lei1, Xin Wang3, Weihua Wu3, Renli Zhang3, Xuan Zou3, Tiejian Feng3, Ruxia Ding4, Yue Zhang4, Yao-Qing Chen1,2, Caijun Sun1,2, Tian Wang5,6,7, Shisong Fang3, Yuelong Shu1,2.   

Abstract

Increasing evidence suggests that dysregulated immune responses are associated with the clinical outcome of coronavirus disease 2019 (COVID-19). Nucleocapsid protein (NP)-, spike (S)-, receptor binding domain (RBD)- specific immunoglobulin (Ig) isotypes, IgG subclasses and neutralizing antibody (NAb) were analyzed in 123 serum from 63 hospitalized patients with severe, moderate, mild or asymptomatic COVID-19. Mild to modest correlations were found between disease severity and antigen specific IgG subclasses in serum, of which IgG1 and IgG3 were negatively associated with viral load in nasopharyngeal swab. Multiple cytokines were significantly related with antigen-specific Ig isotypes and IgG subclasses, and IL-1β was positively correlated with most antibodies. Furthermore, the old patients (≥ 60 years old) had higher levels of chemokines, increased NAb activities and SARS-CoV-2 specific IgG1, and IgG3 responses and compromised T cell responses compared to the young patients (≤ 18 years old), which are related with more severe cases. Higher IgG1 and IgG3 were found in COVID-19 patients with comorbidities while biological sex had no effect on IgG subclasses. Overall, we have identified diseases severity was related to higher antibodies, of which IgG subclasses had weakly negative correlation with viral load, and cytokines were significantly associated with antibody response. Further, advancing age and comorbidities had obvious effect on IgG1 and IgG3.
Copyright © 2021 Luo, Jia, Chen, Zeng, Qiu, Wu, Li, Lei, Wang, Wu, Zhang, Zou, Feng, Ding, Zhang, Chen, Sun, Wang, Fang and Shu.

Entities:  

Keywords:  COVID-19; IgG subclasses; SARS-CoV-2; antibody response; cytokine production; disease severity; host immune response

Mesh:

Substances:

Year:  2021        PMID: 33763078      PMCID: PMC7982848          DOI: 10.3389/fimmu.2021.632814

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  46 in total

1.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.

Authors:  Quan-Xin Long; Xiao-Jun Tang; Qiu-Lin Shi; Qin Li; Hai-Jun Deng; Jun Yuan; Jie-Li Hu; Wei Xu; Yong Zhang; Fa-Jin Lv; Kun Su; Fan Zhang; Jiang Gong; Bo Wu; Xia-Mao Liu; Jin-Jing Li; Jing-Fu Qiu; Juan Chen; Ai-Long Huang
Journal:  Nat Med       Date:  2020-06-18       Impact factor: 53.440

2.  Kinetics of viral load and antibody response in relation to COVID-19 severity.

Authors:  Yanqun Wang; Lu Zhang; Ling Sang; Feng Ye; Shicong Ruan; Bei Zhong; Tie Song; Abeer N Alshukairi; Rongchang Chen; Zhaoyong Zhang; Mian Gan; Airu Zhu; Yongbo Huang; Ling Luo; Chris Ka Pun Mok; Manal M Al Gethamy; Haitao Tan; Zhengtu Li; Xiaofang Huang; Fang Li; Jing Sun; Yanjun Zhang; Liyan Wen; Yuming Li; Zhao Chen; Zhen Zhuang; Jianfen Zhuo; Chunke Chen; Lijun Kuang; Junxiang Wang; Huibin Lv; Yongliang Jiang; Min Li; Yimin Lin; Ying Deng; Lan Tang; Jieling Liang; Jicheng Huang; Stanley Perlman; Nanshan Zhong; Jingxian Zhao; J S Malik Peiris; Yimin Li; Jincun Zhao
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

3.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

4.  Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients.

Authors:  Yifan Meng; Ping Wu; Wanrong Lu; Kui Liu; Ke Ma; Liang Huang; Jiaojiao Cai; Hong Zhang; Yu Qin; Haiying Sun; Wencheng Ding; Lingli Gui; Peng Wu
Journal:  PLoS Pathog       Date:  2020-04-28       Impact factor: 6.823

5.  Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset.

Authors:  Bin Lou; Ting-Dong Li; Shu-Fa Zheng; Ying-Ying Su; Zhi-Yong Li; Wei Liu; Fei Yu; Sheng-Xiang Ge; Qian-Da Zou; Quan Yuan; Sha Lin; Cong-Ming Hong; Xiang-Yang Yao; Xue-Jie Zhang; Ding-Hui Wu; Guo-Liang Zhou; Wang-Heng Hou; Ting-Ting Li; Ya-Li Zhang; Shi-Yin Zhang; Jian Fan; Jun Zhang; Ning-Shao Xia; Yu Chen
Journal:  Eur Respir J       Date:  2020-08-27       Impact factor: 16.671

6.  Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.

Authors:  Nigel J Temperton; Paul K Chan; Graham Simmons; Maria C Zambon; Richard S Tedder; Yasuhiro Takeuchi; Robin A Weiss
Journal:  Emerg Infect Dis       Date:  2005-03       Impact factor: 6.883

7.  Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.

Authors:  Mehul S Suthar; Matthew G Zimmerman; Robert C Kauffman; Grace Mantus; Susanne L Linderman; William H Hudson; Abigail Vanderheiden; Lindsay Nyhoff; Carl W Davis; Oluwaseyi Adekunle; Maurizio Affer; Melanie Sherman; Stacian Reynolds; Hans P Verkerke; David N Alter; Jeannette Guarner; Janetta Bryksin; Michael C Horwath; Connie M Arthur; Natia Saakadze; Geoffrey H Smith; Srilatha Edupuganti; Erin M Scherer; Kieffer Hellmeister; Andrew Cheng; Juliet A Morales; Andrew S Neish; Sean R Stowell; Filipp Frank; Eric Ortlund; Evan J Anderson; Vineet D Menachery; Nadine Rouphael; Aneesh K Mehta; David S Stephens; Rafi Ahmed; John D Roback; Jens Wrammert
Journal:  Cell Rep Med       Date:  2020-06-08

8.  Distinct Early Serological Signatures Track with SARS-CoV-2 Survival.

Authors:  Caroline Atyeo; Stephanie Fischinger; Tomer Zohar; Matthew D Slein; John Burke; Carolin Loos; Denise J McCulloch; Kira L Newman; Caitlin Wolf; Jingyou Yu; Kiel Shuey; Jared Feldman; Blake Marie Hauser; Tim Caradonna; Aaron G Schmidt; Todd J Suscovich; Caitlyn Linde; Yongfei Cai; Dan Barouch; Edward T Ryan; Richelle C Charles; Douglas Lauffenburger; Helen Chu; Galit Alter
Journal:  Immunity       Date:  2020-07-30       Impact factor: 31.745

9.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model.

Authors:  Thomas F Rogers; Fangzhu Zhao; Deli Huang; Nathan Beutler; Alison Burns; Wan-Ting He; Oliver Limbo; Chloe Smith; Ge Song; Jordan Woehl; Linlin Yang; Robert K Abbott; Sean Callaghan; Elijah Garcia; Jonathan Hurtado; Mara Parren; Linghang Peng; Sydney Ramirez; James Ricketts; Michael J Ricciardi; Stephen A Rawlings; Nicholas C Wu; Meng Yuan; Davey M Smith; David Nemazee; John R Teijaro; James E Voss; Ian A Wilson; Raiees Andrabi; Bryan Briney; Elise Landais; Devin Sok; Joseph G Jardine; Dennis R Burton
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

10.  A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients.

Authors:  Yuxin Chen; Xin Tong; Yang Li; Bin Gu; Jiawei Yan; Yong Liu; Han Shen; Rui Huang; Chao Wu
Journal:  PLoS Pathog       Date:  2020-09-10       Impact factor: 6.823

View more
  23 in total

1.  Editorial: Complement and COVID-19 Disease.

Authors:  Zoltán Prohászka; Nicolas S Merle
Journal:  Front Immunol       Date:  2022-07-01       Impact factor: 8.786

2.  Long-Term Follow-Up Study of COVID-19: Evaluation on Thin-Slice CT.

Authors:  Chun-Shuang Guan; Zhi-Juan Liu; Yan-Ni Du; Ru-Ming Xie; Bu-Dong Chen; Hui Chen; Yan Bai; Zhi-Bin Lv; Yan-Li Xu
Journal:  Infect Drug Resist       Date:  2022-10-18       Impact factor: 4.177

3.  Continued Virus-Specific Antibody-Secreting Cell Production, Avidity Maturation and B Cell Evolution in Patients Hospitalized with COVID-19.

Authors:  Maggie L Bartlett; San Suwanmanee; Nadine Peart Akindele; Shristi Ghimire; Andy K P Chan; Chenxu Guo; Stephen J Gould; Andrea L Cox; Diane E Griffin
Journal:  Viral Immunol       Date:  2022-03-14       Impact factor: 2.175

4.  IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma Pools.

Authors:  Christina Kober; Sandro Manni; Svenja Wolff; Thomas Barnes; Shatanik Mukherjee; Thomas Vogel; Lea Hoenig; Peter Vogel; Aaron Hahn; Michaela Gerlach; Martin Vey; Eleonora Widmer; Björn Keiner; Patrick Schuetz; Nathan Roth; Uwe Kalina
Journal:  PLoS One       Date:  2022-01-04       Impact factor: 3.240

5.  Long-term specific IgG response to SARS-CoV-2 nucleocapsid protein in recovered COVID-19 patients.

Authors:  Jira Chansaenroj; Ritthideach Yorsaeng; Nawarat Posuwan; Jiratchaya Puenpa; Nasamon Wanlapakorn; Natthinee Sudhinaraset; Manit Sripramote; Piti Chalongviriyalert; Supunee Jirajariyavej; Phatharaporn Kiatpanabhikul; Jatuporn Saiyarin; Chulikorn Soudon; Orawan Thienfaidee; Thitisan Palakawong Na Ayuthaya; Chantapat Brukesawan; Chintana Chirathaworn; Duangnapa Intharasongkroh; Dootchai Chaiwanichsiri; Mila Issarasongkhram; Rungrueng Kitphati; Anek Mungaomklang; Pijaya Nagavajara; Yong Poovorawan
Journal:  Sci Rep       Date:  2021-12-01       Impact factor: 4.379

6.  Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for SARS-CoV-2 Variants after Primary and Booster Immunization.

Authors:  Hui Xie; Xiaojing Wen; Juan Li; Weixin Chen; Meng Chen; Lichi Zhang; Min Lv; Shanshan Zhou; Shuang Bai; Wei Zhao; Jian Wang; Jiang Wu
Journal:  Int J Infect Dis       Date:  2022-02-02       Impact factor: 12.074

7.  Single-Cell Analysis Reveals the Immune Characteristics of Myeloid Cells and Memory T Cells in Recovered COVID-19 Patients With Different Severities.

Authors:  Xu Li; Manik Garg; Tingting Jia; Qijun Liao; Lifang Yuan; Mao Li; Zhengyu Wu; Weihua Wu; Yalan Bi; Nancy George; Irene Papatheodorou; Alvis Brazma; Huanle Luo; Shisong Fang; Zhichao Miao; Yuelong Shu
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 7.561

8.  Hypozincemia in COVID-19 Patients Correlates With Stronger Antibody Response.

Authors:  Wenye Xu; Yingzhi Liu; Xuan Zou; Huanle Luo; Weihua Wu; Junjie Xia; Matthew T V Chan; Shisong Fang; Yuelong Shu; William K K Wu; Lin Zhang
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

9.  Clinical and antibody characteristics reveal diverse signatures of severe and non-severe SARS-CoV-2 patients.

Authors:  Hongye Wang; Dongshan Yan; Ya Li; Yanfei Gong; Yulin Mai; Bingxiang Li; Xiaoyong Zhu; Xinrui Wan; Liyun Xie; HuaKe Jiang; Min Zhang; Ming Sun; Yufeng Yao; Yongzhang Zhu
Journal:  Infect Dis Poverty       Date:  2022-02-02       Impact factor: 4.520

10.  Immunogenicity of BNT162b2, BBIBP-CorV and Gam-COVID-Vac vaccines and immunity after natural SARS-CoV-2 infection-A comparative study from Novi Sad, Serbia.

Authors:  Vladimir Petrović; Vladimir Vuković; Aleksandra Patić; Miloš Marković; Mioljub Ristić
Journal:  PLoS One       Date:  2022-02-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.